Immunai news

New York City- and Tel Aviv-based Immunai said the acquisition would allow it to expand its target discovery and drug development capabilities and that Nebion`s experience curating public gene expression datasets would help Immunai grow its Annotated Multiomic Immunological Cell Atlas, or AMICA.

"As with other machine learning endeavors like autonomous driving or NLP, having the right data is key," Noam Solomon, Immunai CEO and cofounder, said in a statement. "We`re thrilled to bring

Shortly after raising $60 million to fuel its artificial intelligence work, aimed at digitally charting the human body’s immune system, Immunai announced it has acquired the single-cell sequencing software startup Dropprint Genomics.

Immunai, meanwhil

Immunai has taken some important steps toward its quest to map the entire immune system by completing its second acquisition this year and bolstering its management and board with new executive and entrepreneurial expertise.

Immunai has acquired the Swiss-based biocuration and data integration company Nebion for an undisclosed sum. The deal should extend Immunai’s target discovery and drug development capabilities with Nebion’s curated datasets, discovery tools, and servic

With a recently closed $60 million funding round, the acquisition of software company Dropprint Genomics, and additions to its leadership team, immune profiling firm Immunai is looking to expand its functional genomics capabilities to